Involvement and Functional Impairment of the CD34(+)CD38(-)Thy-1(+) Hematopoietic Stem Cell Pool in Myelodysplastic Syndromes with Trisomy 8
Overview
Authors
Affiliations
Clonality studies of mature cells suggest that the primary transformation event in myelodysplastic syndrome (MDS) most frequently occurs in a myeloid-restricted progenitor, a hypothesis supported by recent studies of purified CD34(+)Thy1(+) hematopoietic stem cells (HSCs) in cases with trisomy 8 (+8). In contrast, we recently demonstrated that a lymphomyeloid HSC is the target for transformation in MDS cases with del(5q), potentially reflecting heterogeneity within MDS. However, since +8 is known to frequently be a late event in the MDS transformation process, it remained a possibility that CD34(+)CD38(-)Thy1(+) HSC disomic for chromosome 8 might be part of the MDS clone. In the present studies, although a variable fraction of CD34(+)CD38(-)Thy1(+) cells were disomic for chromosome 8, they did not possess normal HSC activity in long-term cultures and nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice. Mixing experiments with normal CD34(+)CD38(-) cells suggested that this HSC deficiency was intrinsic and not mediated by indirect mechanisms. Furthermore, investigation of 4 MDS cases with combined del(5q) and +8 demonstrated that the +8 aberration was always secondary to del(5q). Whereas del(5q) invariably occurs in CD34(+)CD38(-)Thy-1(+) HSCs, the secondary +8 event might frequently arise in progeny of MDS HSCs. Thus, CD34(+)CD38(-)Thy1(+) HSCs are invariably part of the MDS clone also in +8 patients, and little HSC activity can be recovered from the CD34(+) CD38(-)Thy1(+) HSC. Finally, in advanced cases of MDS, the MDS reconstituting activity is exclusively derived from the minor CD34(+)CD38(-) HSC population, demonstrating that MDS stem cells have a similar phenotype as normal HSCs, potentially complicating the development of autologous transplantation for MDS.
Das M, Teli P, Vaidya A, Kale V Regen Med. 2024; 19(7-8):407-419.
PMID: 39058408 PMC: 11370962. DOI: 10.1080/17460751.2024.2378627.
van Spronsen M, Hanekamp D, Westers T, van Gils N, Vermue E, Rutten A Leukemia. 2023; 37(3):680-690.
PMID: 36792658 PMC: 9991914. DOI: 10.1038/s41375-023-01811-5.
The Mesenchymal Niche in Myelodysplastic Syndromes.
Friedrich C, Kosmider O Diagnostics (Basel). 2022; 12(7).
PMID: 35885544 PMC: 9320414. DOI: 10.3390/diagnostics12071639.
Stem Cells in the Myelodysplastic Syndromes.
Zhan D, Park C Front Aging. 2022; 2:719010.
PMID: 35822030 PMC: 9261372. DOI: 10.3389/fragi.2021.719010.
The Coming of Age of Preclinical Models of MDS.
Liu W, Teodorescu P, Halene S, Ghiaur G Front Oncol. 2022; 12:815037.
PMID: 35372085 PMC: 8966105. DOI: 10.3389/fonc.2022.815037.